UA115373C2 - Стабільний рідкий склад amg 416 (велкалсетиду) - Google Patents

Стабільний рідкий склад amg 416 (велкалсетиду)

Info

Publication number
UA115373C2
UA115373C2 UAA201600641A UAA201600641A UA115373C2 UA 115373 C2 UA115373 C2 UA 115373C2 UA A201600641 A UAA201600641 A UA A201600641A UA A201600641 A UAA201600641 A UA A201600641A UA 115373 C2 UA115373 C2 UA 115373C2
Authority
UA
Ukraine
Prior art keywords
amg
velcalsetid
liquid composition
stable liquid
composition
Prior art date
Application number
UAA201600641A
Other languages
English (en)
Inventor
Дерек Маклін
Цюнь Інь
Original Assignee
Амген Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115373(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Амген Інк. filed Critical Амген Інк.
Publication of UA115373C2 publication Critical patent/UA115373C2/uk

Links

Classifications

    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04DNON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00Pumping installations or systems
    • F04D25/02Units comprising pumps and their driving means
    • F04D25/06Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01DNON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10Adaptations for driving, or combinations with, electric generators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід стосується фармацевтичного складу, що включає AMG 416 у водному розчині, де склад має pH від 2,0 до 5,0.
UAA201600641A 2013-06-28 2014-06-27 Стабільний рідкий склад amg 416 (велкалсетиду) UA115373C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28
PCT/US2014/044622 WO2014210489A1 (en) 2013-06-28 2014-06-27 Stable liquid formulation of amg 416 (velcalcetide)

Publications (1)

Publication Number Publication Date
UA115373C2 true UA115373C2 (uk) 2017-10-25

Family

ID=51213030

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201600641A UA115373C2 (uk) 2013-06-28 2014-06-27 Стабільний рідкий склад amg 416 (велкалсетиду)

Country Status (38)

Country Link
US (4) US9820938B2 (uk)
EP (3) EP3246017B1 (uk)
JP (1) JP6027708B2 (uk)
KR (1) KR102231957B1 (uk)
CN (2) CN114376970A (uk)
AP (1) AP2015008936A0 (uk)
AR (1) AR096773A1 (uk)
AU (1) AU2014302122B2 (uk)
CA (1) CA2916222C (uk)
CL (1) CL2015003738A1 (uk)
CR (2) CR20160002A (uk)
CY (1) CY1120811T1 (uk)
DK (1) DK3013318T3 (uk)
EA (1) EA030220B1 (uk)
ES (1) ES2633989T3 (uk)
HR (1) HRP20171092T1 (uk)
HU (1) HUE034209T2 (uk)
IL (1) IL243210B (uk)
JO (1) JO3817B1 (uk)
LT (1) LT3013318T (uk)
MA (1) MA38724B1 (uk)
ME (1) ME02818B (uk)
MX (1) MX2015017952A (uk)
MY (1) MY180276A (uk)
PE (2) PE20210413A1 (uk)
PH (1) PH12015502816B1 (uk)
PL (1) PL3013318T3 (uk)
PT (1) PT3013318T (uk)
RS (1) RS56238B1 (uk)
SG (1) SG11201510647TA (uk)
SI (1) SI3013318T1 (uk)
SM (1) SMT201700401T1 (uk)
TN (1) TN2015000569A1 (uk)
TW (1) TWI635874B (uk)
UA (1) UA115373C2 (uk)
UY (1) UY35636A (uk)
WO (1) WO2014210489A1 (uk)
ZA (1) ZA201600238B (uk)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115373C2 (uk) 2013-06-28 2017-10-25 Амген Інк. Стабільний рідкий склад amg 416 (велкалсетиду)
EP3708576B1 (en) 2014-04-03 2023-02-22 Amgen Inc. Method for preparing amg 416
JP6783787B2 (ja) * 2015-03-26 2020-11-11 アムジェン インコーポレイテッド エテルカルセチドの調製のための液相方法
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
WO2021231960A1 (en) 2020-05-15 2021-11-18 Amgen Inc. Methods of treating left ventricle hypertrophy
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (en) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Etelcalcetide formulations for parenteral use
JP2024517801A (ja) 2021-05-06 2024-04-23 アムジエン・インコーポレーテツド エテルカルセチド製剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5158098A (en) 1996-10-25 1998-05-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for inhibiting inflammation and angiogenesis compri sing a mammalian CD97 alpha subunit
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
WO2004105781A2 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
EP2086321B1 (en) 2006-11-16 2016-08-31 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
CA2989778C (en) * 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
EP2264138B2 (en) 2009-06-19 2023-03-08 The Procter & Gamble Company Liquid hand dishwashing detergent composition
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
WO2012170955A1 (en) 2011-06-08 2012-12-13 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法
UA115373C2 (uk) 2013-06-28 2017-10-25 Амген Інк. Стабільний рідкий склад amg 416 (велкалсетиду)
EP3708576B1 (en) * 2014-04-03 2023-02-22 Amgen Inc. Method for preparing amg 416

Also Published As

Publication number Publication date
TWI635874B (zh) 2018-09-21
KR102231957B1 (ko) 2021-03-25
CL2015003738A1 (es) 2016-12-09
US10344765B2 (en) 2019-07-09
US20220042515A1 (en) 2022-02-10
EP3878433A1 (en) 2021-09-15
HUE034209T2 (en) 2018-02-28
EP3013318B1 (en) 2017-04-19
PE20210413A1 (es) 2021-03-04
US11162500B2 (en) 2021-11-02
JP6027708B2 (ja) 2016-11-16
EA201690099A1 (ru) 2016-06-30
EP3013318A1 (en) 2016-05-04
SI3013318T1 (sl) 2017-11-30
MA38724B1 (fr) 2017-11-30
EP3246017B1 (en) 2021-03-24
MY180276A (en) 2020-11-26
ME02818B (me) 2018-01-20
US20190285074A1 (en) 2019-09-19
AR096773A1 (es) 2016-02-03
HK1222557A1 (en) 2017-07-07
RS56238B1 (sr) 2017-11-30
HRP20171092T1 (hr) 2017-10-06
UY35636A (es) 2015-01-30
CA2916222C (en) 2021-05-18
AU2014302122B2 (en) 2018-12-06
CN105764487A (zh) 2016-07-13
CA2916222A1 (en) 2014-12-31
AU2014302122A1 (en) 2016-01-21
NZ715403A (en) 2020-10-30
AP2015008936A0 (en) 2015-12-31
TW201542239A (zh) 2015-11-16
ZA201600238B (en) 2017-05-31
BR112015032615A2 (pt) 2017-07-25
LT3013318T (lt) 2017-09-11
WO2014210489A1 (en) 2014-12-31
MA38724A1 (fr) 2017-03-31
PL3013318T3 (pl) 2018-03-30
CR20160002A (es) 2018-02-13
DK3013318T3 (en) 2017-08-07
ES2633989T3 (es) 2017-09-26
IL243210A0 (en) 2016-02-29
PH12015502816A1 (en) 2016-03-21
MX2015017952A (es) 2016-10-28
CN114376970A (zh) 2022-04-22
EP3246017A1 (en) 2017-11-22
JP2016523916A (ja) 2016-08-12
US20180080452A1 (en) 2018-03-22
PE20160549A1 (es) 2016-06-15
SMT201700401T1 (it) 2017-09-07
JO3817B1 (ar) 2021-01-31
CR20160061A (es) 2016-09-28
PT3013318T (pt) 2017-07-24
EA030220B1 (ru) 2018-07-31
US11959486B2 (en) 2024-04-16
TN2015000569A1 (en) 2017-04-06
IL243210B (en) 2020-02-27
PH12015502816B1 (en) 2016-03-21
KR20160043954A (ko) 2016-04-22
US20160220486A1 (en) 2016-08-04
US9820938B2 (en) 2017-11-21
SG11201510647TA (en) 2016-01-28
CY1120811T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX395015B (es) Composiciones microencapsuladas de cannabinoides
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UY34763A (es) Inhibidores de la agregación plaquetaria
PL3060229T3 (pl) Stabilne, wodne formulacje przeciwciała
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
AR098168A1 (es) Formulación estable de insulina glulisina
HUE054186T2 (hu) Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
EP2953470A4 (en) 2,6,7-SUBSTITUTED PURINS AS HDM2 INHIBITORS
EA201791716A1 (ru) Фармацевтический состав
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
ES2651188T8 (es) Composición líquida fotopolimerizable
EA201990093A1 (ru) Двухкомпонентная композиция
UA116372C2 (uk) Частинки резинату фенілефрину
EA201890597A1 (ru) Содержащая цинеол водная композиция для назального применения